SCHEMBL3985227

SCHEMBL3985227

O=c1[nH]c(CBr)nc2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 3/20 0.70
KMT2A Q03164 2/20 0.68
PDE10A Q9Y233 2/20 0.64
PARP1 P09874 4/20 0.62
RAB9A P51151 2/20 0.62
PARP2 Q9UGN5 1/20 0.62
POLB P06746 1/20 0.60
KDM4E B2RXH2 2/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
MEN1 O00255 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
RET P07949 1/20 0.56
KDR P35968 1/20 0.56
QTRT1 Q9BXR0 1/20 0.56
NPC1 O15118 1/20 0.55
TNKS O95271 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31716684 1.00 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL5740404 0.86 PDE10A (0.69) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL16404338 0.85 PDE10A (0.84) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL19673854 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL2178119 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL1685046 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL30176850 0.82 TNKS2 (1.00) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL29967198 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL30552887 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A
SCHEMBL30259339 0.82 TNKS2 (0.70) TNKS2KMT2APDE10APARP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1164938-A None JP disclosed
CN-104803927-B Chalcone analog of the base containing 2 methyl, 4 oxoquinazolin 6 and its production and use 首都师范大学 2017-11-07 CN disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-7473790-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same PFIZER INC. (US) 2009-01-06 US disclosed
US-20070232673-A1 2-Imino-benzimidazoles ABBOTT LABORATORIES 2007-10-04 US disclosed
US-7148226-B2 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. (US) 2006-12-12 US disclosed
US-20060189681-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME AGOURON PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1597246-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2005-11-23 EP disclosed
US-20050176701-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same AGOURON PHARMACEUTICALS, INC. 2005-08-11 US disclosed
WO-2004074270-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2004-09-02 WO disclosed
EP-0801329-B1 RADIATION-SENSITIVE COMPOSITION AND RECORDING MEDIUM PRODUCED THEREFROM CLARIANT FINANCE BVI LTD (VG) 2002-03-27 EP disclosed
US-6110639-A Radiation-sensitive composition and recording medium using the same HOECHST JAPAN LIMITED (JP) 2000-08-29 US disclosed
EP-0801329-A1 RADIATION-SENSITIVE COMPOSITION AND RECORDING MEDIUM PRODUCED THEREFROM HOECHST JAPAN LIMITED (JP) 1997-10-15 EP disclosed
JP-H01164938-A PHOTOPOLYMERIZABLE COMPOSITION AND PHOTOGRAPHIC MEMBERS HOECHST CELANESE CORP 1989-06-29 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232673-A1 2-Imino-benzimidazoles CYP2C19, UGT2B7, UGT2B17 TNKS2 1072/4885KMT2A 1857/4885PDE10A 2372/4885
US-20060189681-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME RNASE1, RNASEH1, NSUN3 TNKS2 2703/4885KMT2A 2024/4885PDE10A 2955/4885
US-20050176701-A1 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same RNASE1, RNASEH1, NSUN3 TNKS2 2703/4885KMT2A 2024/4885PDE10A 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.